Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class (Ascending) Administration Route Package Effective Date Package Discontinuation Date Status
62332-0730-31 62332-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
62332-0730-36 62332-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
46708-0730-31 46708-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
46708-0730-36 46708-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
70518-1398-00 70518-1398 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Sept. 4, 2018 In Use
70518-1398-01 70518-1398 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Sept. 30, 2018 In Use
70518-1398-02 70518-1398 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Oct. 18, 2018 In Use
70518-1398-03 70518-1398 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Nov. 15, 2018 In Use
70518-1398-04 70518-1398 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 19, 2021 In Use
70860-0202-10 70860-0202 Pemetrexed disodium Pemetrexed 100.0 mg/4.2mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 Feb. 29, 2024 No Longer Used
72338-0100-01 72338-0100 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 4, 2018 In Use
72338-0101-01 72338-0101 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 4, 2018 In Use
62856-0389-01 62856-0389 Eribulin mesylate Halaven 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous Nov. 15, 2010 In Use
60505-6289-00 60505-6289 Eribulin mesylate Eribulin mesylate 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous May 6, 2024 In Use
68083-0592-01 68083-0592 Eribulin mesylate Eribulin mesylate 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous April 5, 2024 In Use
81298-3890-01 81298-3890 Eribulin Mesylate Eribulin Mesylate 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous July 22, 2024 In Use
00143-9167-01 00143-9167 Eribulin mesylate ERIBULIN MESYLATE 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous June 28, 2024 In Use
66302-0014-01 66302-0014 Dinutuximab Unituxin 3.5 mg/mL Immunotherapy Monoclonal Antibody GD-2 Intravenous March 10, 2015 In Use
73042-0201-01 73042-0201 Naxitamab DANYELZA 40.0 mg/10mL Immunotherapy Monoclonal Antibody GD2 Intravenous Nov. 25, 2020 In Use
57894-0469-01 57894-0469 Talquetamab TALVEY 3.0 mg/1.5mL Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 Subcutaneous Aug. 9, 2023 In Use
57894-0470-01 57894-0470 Talquetamab TALVEY 40.0 mg/mL Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 Subcutaneous Aug. 9, 2023 In Use
55566-8303-01 55566-8303 Degarelix Firmagon Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist March 2, 2009 In Use
55566-8403-01 55566-8403 Degarelix Firmagon Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist March 2, 2009 In Use
55566-8301-00 55566-8301 Degarelix Firmagon Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist March 2, 2009 March 31, 2015 No Longer Used
55566-8301-01 55566-8301 Degarelix Firmagon Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist March 2, 2009 March 31, 2015 No Longer Used

Found 10,000 results in 14 milliseconds — Export these results